非小细胞肺癌患者血清铁蛋白、胸苷激酶1、基质金属蛋白酶9表达及临床价值探讨

详细信息    查看全文 | 推荐本文 |

英文篇名：The expressions of serum ferritin,STK1 and MMP-9 in patients with NSCLC and their clinical values 作者：王总飞 ; 刘先本 ; 张瑞祥 ; 刘士磊 英文作者：WANG Zong-fei;LIU Xian-ben;ZHANG Rui-xiang;LIU Shi-lei;Department of Thoracic Surgery,Affiliated Tumor Hospital,Zhengzhou University; 关键词：铁蛋白 ; 胸苷激酶1 ; 基质金属蛋白酶9 ; 非小细胞肺癌 ; 表达 英文关键词：Ferritin;;Thymidine kinase 1;;Matrix metalloproteinase 9;;Non-small cell lung cancer;;Expression 中文刊名：YYLC 英文刊名：Practical Journal of Clinical Medicine 机构：郑州大学附属肿瘤医院胸外科; 出版日期：2019-05-01 出版单位：实用医院临床杂志 年：2019 期：v.16 语种：中文; 页：YYLC201903032 页数：3 CN：03 ISSN：51-1669/R 分类号：111-113

摘要

目的探讨非小细胞肺癌(NSCLC)患者血清铁蛋白(SF)、胸苷激酶1(STK1)、基质金属蛋白酶9(MMP-9)的表达及临床意义。方法我院收治的NSCLC患者80例(观察组)、肺部良性疾病患者65例(对照1组)及健康体检者50例(对照2组),测定各组血清SF、MMP-9、STK1水平,并分析与NSCLS患者病理特征的关系。结果观察组血清SF、MMP-9、STK1水平高于对照1、2组(P <0. 05);鳞癌、III期、淋巴结转移患者血清SF、MMP-9、SKT1水平分别高于腺癌、I～II期、非淋巴结转移患者(P <0. 05); NSCLC患者血清SF与MMP-9、STK1呈正相关(P <0. 05)。结论 NSCLC患者血清SF、MMP-9、STK1水平明显上升,且三者之间呈正相关关系,协同参与NSCLC的发生、进展。
        Objective To investigate the expressions of serum ferritin( SF),thymidine kinase 1( STK1) and matrix metalloproteinase 9( MMP-9) in patients with non-small cell lung cancer( NSCLC) and their clinical significance.Methods Eighty patients with NSCLC( observation group),65 patients with benign pulmonary disease( control group 1) and 50 healthy controls( control group2) who were admitted to our hospital were selected.The levels of serum SF,MMP-9 and STK1 in each group were determined.The relationship between above indexes and pathological features of NSCLC was analyzed.Results The levels of serum SF,MMP-9 and STK1 were significantly higher in the observation group than those in the control group 1 and control group 2( P < 0. 05).The levels of serum SF,MMP-9 and SKT1 in squamous cell carcinoma patients with stage III and lymph node metastases were significantly higher than those in adenocarcinoma patients with stage I ～ II and without lymph node metastases( P < 0. 05). Serum SF was positively correlated with MMP-9 and STK1 in patients with NSCLC( P < 0. 05).Conclusion The levels of serum SF,MMP-9 and STK1 are obviously increased in patients with NSCLC.Serum SF,MMP-9 and STK1 are correlated and involved in the occurrence and progression of NSCLC.

引文

[1]胡余敏,朱君飞.非小细胞肺癌组织中FOXC2和MMP-9的表达及临床意义[J].浙江医学,2017,39(18):1564-1566.
    [2]李爱科,李青山,林萍萍,等.HIF-1α、VEGF及MMP-9在非小细胞肺癌组织中的表达及其意义[J].医学临床研究,2017,34(9):1687-1690.
    [3]蒙飞,王恒,梁鑫,等.肿瘤标志物联合检测在非小细胞肺癌诊断中的应用价值[J].国际检验医学杂志,2014,35(19):2638-2639,2643.
    [4]黄志宇,李建成,郑步宏,等.血清胸苷激酶1水平与晚期非小细胞肺癌含培美曲塞方案疗效的关系分析[J].临床肿瘤学杂志,2017,22(9):792-796.
    [5]李铭,胡广原,梅齐,等.血清胸苷激酶1的检测在非小细胞肺癌诊断及疗效评估中的意义[J].中国医药导刊,2017,19(5):435-437.
    [6]陈鹏,董绍安,由玉梅,等.非小细胞肺癌组织中MMP-9、Ecadherin的表达变化及其意义[J].山东医药,2017,57(25):93-95.
    [7]Orlandi R,De Bortoli M,Ciniselli CM,et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer[J].Ann Oncol,2014,25(2):352-357.
    [8]范国华,江文洋,黄杰,等.肺癌患者血清铁蛋白的表达及临床意义[J].临床外科杂志,2015,23(4):303-304.
    [9]周晶,王莉娜,兀威,等.血清SF、CEA和CRP联合检测诊断非小细胞肺癌的价值[J].海南医学,2015,26(20):3015-3018.
    [10]Wang JL,Wu DW,Cheng ZZ,et al. Expression of high mobility group box-B1(HMGB-1)and matrix metalloproteinase-9(MMP-9)in non-small cell lung cancer(NSCLC)[J].Asian Pac J Cancer Prev,2014,15(12):4865-4869.
    [11]徐晓艳,裴陆田,李秀霞,等.非小细胞肺癌中MMP-9和MMP-13的表达及意义[J].临床与实验病理学杂志,2014,30(12):1358-1364.
    [12]梁乃超.MMP-9和VEGF在非小细胞肺癌患者中的表达情况[J].医学综述,2017,23(9):1867-1869.
    [13]El-Badrawy MK,Yousef AM,Shaalan D,et al.Matrix metallopro-teinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity,pathologic type,and prognosis[J].J Bronchology Interv Pulmonol,2014,21(4):327-334.
    [14]Bolayirli M,Papila C,Korkmaz GG,et al.Serum thymidine kinase 1activity in solid tumor(breast and colorectal cancer)patients treated with adjuvant chemotherapy[J]. J Clin Lab Anal,2013,27(3):220-226.
    [15]黄仁飞,江倩,金蒙蒙,等.血清胸苷激酶1评估非小细胞肺癌化疗疗效的意义[J].实用医学杂志,2016,32(17):2840-2843.
    [16]Benjamin N,Hovav N,Haim B,et al.Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients:A Brief Report[J]. J Thorac Oncol,2014,9(10):1568-1572.